July 1, Hybribio(300639) announced that the company and its subsidiaries have recently obtained authorization for an invention patent. The patent is called "Method, device and equipment for processing genome copy number variation analysis data", the patent number is 202510354669.9, and the country of grant is China. The patent holders include Guangzhou Cap Medical Laboratory Co., Ltd., Guangzhou Cap Medical Laboratory Development Co., Ltd. and the company itself.

The invention relates to the field of bioinformatics and provides a data screening logic and conditions that can accurately present the CNV results of the whole genome. This method can reduce interference information and improve the accuracy and readability of the interpretation of the test results. The company said that obtaining this patent is in line with its development strategy and will not have a significant impact on the current business situation, but it will help improve intellectual property rights.system to enhance core competitiveness.

In the first quarter of 2025, KeyGen Bio achieved revenue of 134 million yuan and a net profit attributable to shareholders of the parent company of -27.3 million yuan.

https://finance.eastmoney.com/a/202507013445127898.html